News | October 10, 2025
AstraZeneca to increase investment in Virginia manufacturing facility to $4.5 billion
Facility marks cornerstone of $50 billion investment in medicines R&D and manufacturing in America
Facility marks cornerstone of $50 billion investment in medicines R&D and manufacturing in America
The new line features advanced isolator technology to deliver enhanced sterility assurance, throughput and operational precision
The company plans to use the funds raised from the net proceeds to repay or prepay certain loans
New filling line approval supports delivery of integrated, end-to-end solutions across the entire biologics and bioconjugates value chain
Furthering?U.S.-based?pharmaceutical?capacity?to?produce?critical respiratory medicines?
New offering to debut at the 32nd ESGCT Congress, October 7–10, 2025, in Seville, Spain
Lonza boosts TheraPEAK line with new Cytokines and AAV Medium for next-gen therapies
It represents a 30% increase in the company’s production capacity and introduces a segment dedicated to highly potent active ingredients
Investment to expand manufacturing and global medicine supply capacity
Marks first international filing for Evofem’s single-dose oral treatment
Subscribe To Our Newsletter & Stay Updated
